Skip to content
Bills from the 2023–24 session

Senate Bill 783

Therapeutic interchange for drug products prescribed to counteract anaphylaxis

Stopped in committee

It had a but no committee vote, so it never came up for a vote. To try again, a lawmaker would have to start a new bill.

  1. Introduced, passed

    Dec 8, 2023

  2. Committee, stopped here

    Stopped here. It had a hearing but no committee vote.

  3. Senate vote, not reached

  4. Assembly vote, not reached

  5. Governor, not reached

  6. Law, not reached

Latest entry in the official record, Apr 15, 2024: “Failed to pass pursuant to ⁠”

It sat with the Senate Committee on Health.

Read the bill

Following saves it on this device. New actions show on your Following page. You can also get updates in a feed reader.

Embed this on your site

Paste this code into your page. The card shows the latest record each time it loads. Preview the card

What it would have done

Summary by the , the Legislature's nonpartisan drafting office. It's their wording, not ours.

This bill allows a pharmacist to substitute a drug product prescribed to counteract anaphylaxis with another drug product that would, in the opinion of the pharmacist, have a substantially equivalent therapeutic effect even though the substitute drug product is not a drug product equivalent if certain conditions are met.

The bill also provides that a pharmacist who dispenses a drug product for a patient in a hospital may, for a drug product prescribed to counteract anaphylaxis, under the same conditions applicable for drug product equivalents under current law, substitute a drug product with another drug product that would, in the opinion of the pharmacist, have a substantially equivalent therapeutic effect even though the substitute drug product is not a drug product equivalent. Current law defines a “drug product equivalent” as a drug product that is designated the therapeutic equivalent of another drug product by the federal Food and Drug Administration as set forth in the latest edition of the supplement to the federal Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations , commonly known as the Orange Book. As with substitution of drug product equivalents under current law, the therapeutic substitutions allowed under the bill do not apply to biological products.

Who's behind it

4 senators are its ⁠. All 4 are Democrats.

18 more lawmakers ⁠.

See all 22 names

Authors (4)

Signed on in support (18)

What happened

  1. Apr 15, 2024

    The session ended, and the bill died with it.

  2. Jan 25, 2024

    1 more representative signed on in support.

  3. Jan 18, 2024

    The committee held a public hearing.

  4. Dec 14, 2023 to Dec 22, 2023

    1 more representative and 1 senator signed on in support.

  5. Dec 8, 2023

    Sent to the Senate Committee on Health.

  6. Dec 8, 2023

    Introduced in the Senate.

See the official record, word for word
  1. Dec 8, 2023 · Senate

    Introduced by Senators Spreitzer, Smith, Taylor and Wirch; cosponsored by Representatives Vining, C. Anderson, J. Anderson, Clancy, Conley, Considine, Drake, Emerson, Joers, Madison, Ohnstad, Ortiz-Velez, Ratcliff, Shankland and Sinicki

  2. Dec 8, 2023 · Senate

    Read first time and referred to Committee on Health

  3. Dec 14, 2023 · Senate

    Senator Agard added as a coauthor

  4. Dec 22, 2023 · Senate

    Representative Subeck added as a cosponsor

  5. Jan 18, 2024 · Senate

    Public hearing held

  6. Jan 25, 2024 · Senate

    Representative Haywood added as a cosponsor

  7. Apr 15, 2024 · Senate

    Failed to pass pursuant to Senate Joint Resolution 1

Terms on this page

Committee

A small group of lawmakers that looks at a bill first. Most bills never leave committee.

More in the glossary

Public hearing

A meeting where anyone can speak to a committee about a bill, or send written comments.

More in the glossary

Senate Joint Resolution 1

The session's calendar. Any bill not passed by its last voting day dies.

Official term: Failed to pass pursuant to SJR 1. More in the glossary

Legislative Reference Bureau

The Legislature's nonpartisan office that drafts bills and writes the summary at the top of each one.

Official term: LRB analysis. More in the glossary

Author

A lawmaker who formally puts a bill forward. The text itself is drafted by the Legislative Reference Bureau.

Official term: Author, coauthor. More in the glossary

Signed on in support

Lawmakers who back a bill without being one of its authors, often from the other chamber.

Official term: Cosponsor. More in the glossary

From the Wisconsin Legislature's official record, checked Sep 15, 2026. See the source

Committee

A small group of lawmakers that looks at a bill first. Most bills never leave committee.

Public hearing

A meeting where anyone can speak to a committee about a bill, or send written comments.

Senate Joint Resolution 1

The session's calendar. Any bill not passed by its last voting day dies.

Official term: Failed to pass pursuant to SJR 1

Legislative Reference Bureau

The Legislature's nonpartisan office that drafts bills and writes the summary at the top of each one.

Official term: LRB analysis

Author

A lawmaker who formally puts a bill forward. The text itself is drafted by the Legislative Reference Bureau.

Official term: Author, coauthor

Signed on in support

Lawmakers who back a bill without being one of its authors, often from the other chamber.

Official term: Cosponsor